Professor Russell Luepker answers questions about risk factors for heart attacks and strokes, the health benefits of daily aspirin use and who should take aspirin daily for prevention.
Daynamica was co-developed by Associate Professor Julian Wolfson and captures detailed activity and travel information when people are driving, walking, biking, or using mass transit, such as riding a bus.
Adjunct Associate Professor Gary Schwitzer co-authored the study that showed readers were more likely to believe a treatment is beneficial when news stories were reported with spin.
The method developed by Assistant Professor Susan Arnold could help protect consumers by revealing product formulations that are hazardous to health over time.
Adjunct Professor Gary Schwitzer co-authored a JAMA editorial offering insights into the origins of the mistrust — and steps for improving the accuracy and quality — of health journalism.
The PH WINS survey co-developed by researcher JP Leider showed more than 40 percent of governmental public health workers are planning on retiring by 2023 or considering leaving their positions within the next year.
Associate Professor Irina Stepanov talks about heated tobacco products, how the new iQOS device works, and what the potential harms and benefits of iQOS are to public health.
The results of a study led by PhD student Xuanzi Qin suggest the potential benefits of screening may be more readily understood and appreciated by women.
The study results from student Jeremy Van’t Hof and Professor Russell Luepker suggest that people may feel a greater sense of CVD prevention accountability and social support in community settings.
Assistant Professor Eric Lock has received a $1-million grant from the NIH to develop new methods to analyze multi-source and multi-way data all together at the same time.
A study by researcher Stuart Grande shows mHealth apps, such as Genia, help children with Juvenile Idiopathic Arthritis share their needs and experiences with their families and care teams.
Associate Professor Pamela Lutsey found that DOAC drugs appear to be just as safe to use as heparin and warfarin for treating venous thromboembolism in cancer patients.